Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis

BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis. In two randomized (1:1), global, phase 3, open-label, sponsor-blind, pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarnak, Mark J, Agarwal, Rajiv, Boudville, Neil, Chowdhury, Pradip C P, Eckardt, Kai-Uwe, Gonzalez, Carlos R, Kooienga, Laura A, Koury, Mark J, Ntoso, Kwabena A, Luo, Wenli, Parfrey, Patrick S, Vargo, Dennis L, Winkelmayer, Wolfgang C, Zhang, Zhiqun, Chertow, Glenn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539221/
https://www.ncbi.nlm.nih.gov/pubmed/37096396
http://dx.doi.org/10.1093/ndt/gfad074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539221/
https://www.ncbi.nlm.nih.gov/pubmed/37096396
http://dx.doi.org/10.1093/ndt/gfad074

Ejemplares similares